Latest News - Oklahoma Society of Clinical Oncology

Enhertu approved in the US as first tumour-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumours

Based on three Phase II trials of AstraZeneca and Daiichi Sankyo’s Enhertu which showed clinically meaningful responses across a broad range of tumours Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of […]

Read More

AstraZeneca announces results of TOPAZ-1 Phase III Trial

Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial Longest survival follow-up ever reported for immunotherapy treatment in this setting  Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall […]

Read More

Did you miss OSCO’s Presentation of the Best of SABCS® or need to claim continuing education credit? Please see the information below.

OSCO’s recent presentation of the Official Review of the San Antonio Breast Cancer Symposium provided attendees with excellent updates on many breast cancer topics.  The first session was presented by Joyce O’Shaughnessy, MD on HR+ Breast Cancer.  The second session was a Radiation Oncology Update presented by Danushka Seneviratne, MD, PhD.  After a short break […]

Read More

FDA approval of a new pediatric indication for BESPONSA®

Pfizer Oncology is proud to announce the FDA approval of a new pediatric indication for BESPONSA® (inotuzumab ozogamicin). The following information is available for review: ·       Full Prescribing Information Including Boxed Warning

Read More

TAGRISSO (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer

AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval following a Priority Review by the Food and Drug Administration (FDA) was based on the results from the FLAURA2 Phase III trial […]

Read More

New Coding Guidance for Recently Approved Pfizer Oncology Product

The Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection effective for dates of service on or after April 1, 2024 J1323- Injection, elranatamab-bcmm, 1 mg Please see full prescribing information including Boxed Warning, HERE.

Read More

Takeda announces Compassionate Use Program for EXKIVITY

Takeda’s Compassionate Use Program for EXKIVITY is now open for enrollment in the U.S. The withdrawal of EXKIVITY will occur no later than March 2024, with the specific date still to be determined by the US Food and Drug Administration (FDA) based on review of ongoing operational activities related to the withdrawal. • Patients prescribed […]

Read More

Merck provides new information on Treatment for Patients With Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma (MCC)

KEYTRUDA® (pembrolizumab) Injection 100 mg is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic MCC. SELECTED SAFETY INFORMATION Severe and Fatal Immune-Mediated Adverse Reactions to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate. 1 month. Consider administration of other systemic immunosuppressants in […]

Read More

Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer

First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients with specific biomarker alterations (PIK3CA, AKT1 or PTEN). Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in the biomarker-altered population. AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the […]

Read More

Takeda announces that the US Food and Drug Administration has approved FRUZAQLA™ (fruquintinib), an oral therapy for adult patients with previously treated metastatic colorectal cancer (mCRC).1,*

*FRUZAQLA is a kinase inhibitor indicated for the treatment of adult patients with mCRC who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy.1 CRC is the 4th most common cancer in the US, and up to 50% of patients with CRC will […]

Read More